How VYNDAMAX® (tafamidis) works
In a clinical trial, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in people with ATTR-CM.
Transthyretin (TTR) is an important protein primarily produced in the liver. TTR carries thyroxine (a thyroid hormone) and retinol (vitamin A) throughout the body. TTR is mostly made in the liver but is also made in smaller amounts in the outer lining of the brain and retina.
ATTR-CM occurs when the TTR protein weakens and becomes unstable.
VYNDAMAX attaches to the TTR protein.
VYNDAMAX stabilizes TTR, helping it stay together.
By stabilizing TTR, VYNDAMAX slows the breakdown and buildup of dangerous deposits, which can help to slow the progression of ATTR-CM.